Yes (first approved september 28, 2018) brand name See important safety & full prescribing information. Findings showed cemiplimab reduced the risk of disease recurrence or death by 68% compared with placebo The fda evaluated libtayo under priority review, which is reserved for medicines that represent potentially significant improvements in efficacy or safety in the treatment of serious conditions. The fda approves eylea hd the treatment of patients with macular edema following retinal vein occlusion. The following is a message from the director of the fda oncology center of excellence, dr
OPEN
